NeuroNEXT Network

Standard Operating Procedure (SOP)
Concomitant Medications Coding
Version 1.0
SOP NN DM 1007

Originators: NeuroNEXT CCC and DCC Personnel

Reviewed and Approved by:

Christopher S. Coffey, PhD (CCC Principal Investigator)

Merit E. Cudkowicz, MD MSc (CCC Principal Investigator)

Marianne Kearney, BA (CCC Director of Clinical Operations)

Dixie J. Ecklund, RN MSN MBA (DCC Associate Director)

Katherine B. Gloer, PhD (DCC Quality Management Lead)

Claudia Moy, PhD, MPH (NINDS, NeuroNEXT Administrative Program Director)

Issue Date

April 6, 2012

Effective Date (30 calendar days after the Issue Date)

May 6, 2012
NN DM 1007
NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR CONCOMITANT MEDICATIONS CODING

<table>
<thead>
<tr>
<th>SOP: NN DM 1007</th>
<th>CONCOMITANT MEDICATIONS CODING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version No. 1.0</td>
<td>Supercedes</td>
</tr>
<tr>
<td>Effective Date:</td>
<td>Document: N/A</td>
</tr>
<tr>
<td></td>
<td>Effective Date: N/A</td>
</tr>
</tbody>
</table>

1. POLICY

This SOP provides guidance for the coding of concomitant medications and therapeutic products administered to or used by subjects who are participating in clinical trials supported by the NeuroNEXT Network. The NeuroNEXT Data Coordinating Center (DCC) uses a standardized classification system to ensure that clinical trial reports that summarize and categorize medicinal and therapeutic products are concise, easily analyzed, and accurately interpreted.

2. SCOPE

This SOP has been developed to be in alignment with federal regulations and Good Clinical Practices (GCP) as set forth in the 1996 ICH E6 Consolidated Guidance. The policies and procedures described in this SOP apply to the NeuroNEXT Clinical Coordinating Center (CCC) and DCC within the context of their oversight and advisory roles for the NeuroNEXT Network, and to all NeuroNEXT investigators, staff, subcontractors, or other entities associated with the NeuroNEXT Network who manage, oversee, and conduct research regulated by FDA and/or applicable review committees.

3. ROLES AND RESPONSIBILITIES

Depending on the nature and requirements of the study protocol, DCC personnel may be responsible for coding concomitant medications for NeuroNEXT clinical trials.

4. APPLICABLE REGULATIONS AND GUIDELINES

ICH E6 Good Clinical Practice: Consolidated Guidance, April 1996

5. REFERENCES TO OTHER APPLICABLE SOPS

NN BIO 904 Generation and Validation of Analysis Datasets
NN BIO 906 Report Writing

6. ATTACHMENTS AND REFERENCES

NN DM 1007 - A Document History


7. TERMS AND ABBREVIATIONS

The following terms and abbreviations are used in this document:

ATC Code Anatomical-Therapeutic-Chemical classification used for the coding of therapeutic drugs. One drug may code to several ATC codes, depending on its therapeutic applications.
8. SPECIFIC PROCEDURES

A. Concomitant Medications Coding

The term ‘concomitant medication’ refers to any medicinal product that is not a study drug or part of the study protocol, and is taken by or administered to a subject during the course of her/his participation in a clinical trial. These products most often refer to medications, although the concomitant use of other therapeutic products, such as herbal remedies, biologics, dietary supplements, diagnostic substances, or contrast media, may also be of interest in the analysis of clinical trial data. For the purposes of this SOP, the term ‘concomitant medications’ refers to any medicinal or therapeutic product that is used by the subject during the course of a NeuroNEXT clinical trial.

According to the requirements of the protocol, concomitant medication information is recorded on source documents at the clinical site, and is then entered into the electronic data capture (EDC) system through the appropriate electronic Case Report Form (eCRF). Because concomitant medications may be referred to in multiple ways (e.g. a drug may be referred to by its trade name, generic name, or chemical substance name), it is important for quality assurance and data analysis purposes that the names and classifications of these products are standardized. The coding process described below may be employed by the DCC to verify that concomitant medications are accurately represented in the study database and to minimize confusion and ambiguity that may result from the application of multiple naming conventions that may be used by different NeuroNEXT Clinical Study Sites (CSS).

As required by a NeuroNEXT protocol, DCC Biostatisticians may prepare reports containing listings of concomitant medications with coding conventions applied from data that are stored in the study database. The listings are then reviewed by trained DCC personnel to standardize the information. During the coding process, a unique drug code is assigned, along with associated Anatomical/Therapeutic/Chemical (ATC) classification codes. Each drug is coded with an “Official” ATC Code, but a drug also may be referenced to several “Alternative” ATC Codes. The DCC coder will evaluate drugs that are referenced to multiple alternative codes, and will select a common code based on medical review so that identical concomitant medication products are listed under a single name or classification.

The reviewed coding results are used by DCC Biostatisticians to group the concomitant medications data in an analytically meaningful way, and to create final reports that are readily interpreted.
The current version of the World Health Organization Drug Dictionary-Enhanced (WHO-DDE) will be used as a reference during coding for appropriate NeuroNEXT studies. If it is established that the WHO-DDE will not be used for a study, the DCC will collaborate with the PPI and the CCC to develop a standardized system for coding and classification for a study based on WHO or other appropriate coding conventions. The standardized system may be used to standardize drug names, assign drug codes, identify active ingredients, and classify drugs according to their ATC classification.

<table>
<thead>
<tr>
<th>#</th>
<th>Who</th>
<th>Task</th>
<th>Attachment/Reference</th>
<th>Related SOP</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>CCC and DCC</td>
<td>Collaborate to develop a plan for standardizing and tabulating concomitant medications for the NeuroNEXT Network.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>CSS</td>
<td>Submit a list of all concomitant medications for a study subject on the appropriate electronic Case Report Form (eCRF), using the standardized format.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>DCC</td>
<td>In consultation with the PPI and CCC, create a standardized format for tabulating concomitant medications for the study.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>DCC Biostatisticians</td>
<td>For each applicable NeuroNEXT study, create a listing of all concomitant medications that have been submitted to the DCC database through the EDC system.</td>
<td></td>
<td>NN BIO 904</td>
</tr>
<tr>
<td>5.</td>
<td>DCC Coder</td>
<td>Code and classify concomitant medications according to the plan for standardizing and tabulating medicinal and therapeutic products for the study.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>DCC Coder</td>
<td>Categorize concomitant medications by Organ or System and Therapeutic Indication using WHO drug coding guidelines, the WHO-DDE (if applicable), or another agreed-upon coding system.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>DCC Biostatisticians</td>
<td>Generate reports that summarize concomitant medications data for the study.</td>
<td></td>
<td>NN BIO 906</td>
</tr>
</tbody>
</table>